HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF
HUTCHMED (China) Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$14.18+0.13 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 27.3
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Gross margin
38.7%
Operating margin
-7.1%+79.1 pts over 5 years
Net margin
83.3%+138.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -13.0% | +8.8% | +19.2% | +11.9% | |
| Gross profit | -24.6% | +22.5% | – | +11.2% | |
| Net income | +1111.0% | – | – | +49.9% | |
| EPS, diluted | +1200.0% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 8.7% | -32.6% | 45.7% | |
| Return on assets | 4.1% | -21.1% | 30.2% | |
| Current ratio | 1.76 | 3.35 | 4.96 | |
| Debt to equity | 0.25 | 0.06 | 0.10 | |
| Net debt to EBITDA | 0.74× | 1.10× | -1.81× | |
| Interest coverage | -28.6× | -249.9× | -13.7× | |
| Inventory turnover | 13.3× | – | 7.3× | |
| Capex to revenue | 2.0% | 3.5% | 2.6% | |
| Diluted shares | 600M | 698M | 873M |
Where the cash went
Fiscal 2021 to 2025, five years combined
HUTCHMED (China) generated $757.23M from operations and spent $238.29M on capital expenditure, dividends and share buybacks. 49% of that went back into the business.
Generated
$757.23M
Used
$238.29M
Capital expenditure$117.76M49%Dividends$00%Share buybacks$120.53M51%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin83.3%
×Asset turnover0.36×
×Equity multiplier1.52×
=Return on equity, FY202545.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 83.3% | 0.36× | 1.52× | 45.7% |
| FY2024 | 6.0% | 0.49× | 1.71× | 5.1% |
| FY2023 | 12.0% | 0.73× | 1.72× | 15.0% |
| FY2022 | -84.6% | 0.36× | 1.50× | -45.2% |
| FY2021 | -54.7% | 0.34× | 1.43× | -26.5% |
| FY2020 | -55.2% | 0.38× | 1.54× | -32.6% |
| FY2019 | -51.7% | 0.41× | 1.47× | -31.3% |
| FY2018 | -34.9% | 0.38× | 1.33× | -17.6% |
| FY2017 | -11.1% | 0.51× | 1.46× | -8.3% |
| FY2016 | 5.4% | 0.76× | 2.14× | 8.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$456.91M
- Cash generatingOperating cash flow above zero-$64.66M
- Return on assets improvedROA up on the prior year2.9% → 35.9%
- Earnings backed by cashOperating cash flow above net income-$64.66M vs $456.91M
- Less leverageLong-term debt to assets fell4.7% → 3.9%
- Better liquidityCurrent ratio rose2.83 → 4.96
- No dilutionShare count did not rise873M → 873M
- Gross margin improvedGross margin up on the prior year44.64% → 38.68%
- More efficientAsset turnover rose0.49 → 0.43